10 years ago, Sansoul Pharma was founded as a pioneer in the market for reimports and parallel imports of low-cost medicinal products. Our business model lets us combine profitable growth with a measurable reduction in health care costs.
The prices for identical original products vary across ASIA due to the different health care systems in place. In 2014, health care costs in India alone were cut by some 240 million euros thanks to parallel imports and re imports. Furthermore, in India a further 3 billion euros in savings are the indirect result of competitive pressure brought about by trade with EU pharmaceuticals – in particular high-priced products protected by patents: In this segment, imports offer the sole method of controlling pricing and competition and thus keeping the costs of medicinal products down. Pharmacies and patients are unable to use lower-cost generic alternatives.
By importing these products at more attractive conditions, we help pharmacies to make indirect cost savings as a result of purchasing their products from pharmaceutical wholesalers or attractive purchasing conditions when ordering directly.
Full-range provider and trading partner
SANSOUL Pharma offers some 2,900 different pharmaceutical via its distribution subsidiaries . The range includes patented and non-patented products, generic products, and over-the-counter pharmaceuticals, narcotic drugs and medical devices.
Our wide range of products and our above-average delivery capabilities, combined with optimised processes and fair terms, make us a reliable partner to pharmacies and pharmaceutical wholesalers alike. We are also an established trading partner and valued contact for our business partners in the field of high quality contract manufacturing.